Patents Examined by Doug Shultz
  • Patent number: 9649388
    Abstract: Provided are a SAMiRNA-magnetic nanoparticle complex capable of effectively delivering a double-stranded oligo RNA and magnetic nanoparticles into a cell and a composition capable of simultaneously performing diagnosis and therapy of diseases such as cancer, and the like, containing the same. More specifically, provided is the SAMiRNA-magnetic nanoparticle complex consisting of double-stranded oligo RNA-polymer structures in which a hydrophilic material and a second hydrophobic material are bound to the double-stranded oligo RNA by a simple covalent bond or a linker-mediated covalent bond, and the magnetic nanoparticles in which a first hydrophobic material is bound onto a surface of the magnetic material, as a core. The SAMiRNA-magnetic nanoparticle complex may have a homogeneous size by a hydrophobic interaction between the first hydrophobic material of the present invention and the second hydrophobic material of the double-stranded oligo RNA structure.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: May 16, 2017
    Assignee: BIONEER CORPORATION
    Inventors: Jeiwook Chae, Hyunjin Chung, Boreum Lee, Han Oh Park
  • Patent number: 8703180
    Abstract: Disclosed are compositions with sustained-release carriers associated with at least two different types of growth factors and methods of fabrication and treatments thereof. In some embodiments, simultaneous release of the growth factors may be preferred while in other embodiments, sequential release of the growth factors may be preferred. Application of at least two growth factors to an injury site, e.g., compromised cardiac tissue caused by, for example, myocardial infarction or ischemic heart failure, may better mimic and induce the complex growth factor signaling pathways necessary to improve cardiac function. When applied to a patient after a myocardial infarction or ischemic heart failure, multiple growth factors within a sustained-release carrier platform or platforms may cause a synergistic effect on injected cells intending to alleviate left ventricle remodeling. Methods of treatment include percutaneous, sub-xiphoid, and open chest methods using catheters and/or syringes.
    Type: Grant
    Filed: October 23, 2007
    Date of Patent: April 22, 2014
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventors: John J. Stankus, Florian N. Ludwig, Evgenia Mandrusov, Liangxuan Zhang, Hong Ma, Jinping Wan, Shubhayu Basu